Small-cell lymphoma and Sjögren's syndrome. Lymphoplasmacytic subvariant of small-cell lymphoma with IgA/kappa immunoglobulin surface markers.

To our knowledge, the association of the plasmacytoid variety of small-cell lymphoma with primary Sjögren's syndrome has not been reported. We describe a patient with SS who developed plasmacytoid small-cell lymphoma. As opposed to the commonly detected IgM, the lymphocyte surface immunoglobulins contained monoclonal IgA/kappa light chains.

Periorbital ecchymoses as the initial sign in multiple myeloma.

A 61-year-old man with bilateral recurrent periorbital ecchymoses was followed up for 36 months, at which time the diagnosis of multiple myeloma was established. However, in vitro tests of blood coagulation and platelet function gave normal findings. A biopsy specimen of the ecchymotic area showed no evidence of amyloid.

Antigranulocyte antibodies and deranged immune function associated with phenytoin-induced serum sickness.

A phenytoin-associated serum-sickness-like syndrome was followed by severe pancytopenia in a 17-year-old female. Serum obtained during the acute phase of her illness contained antibodies against homologous eosinophils and neutrophils, antibodies against autologous neutrophils, and antibodies to phenytoin. The serum also inhibited bone marrow granulocyte colon formation in vitro.

Advances in adult non-Hodgkin's lymphoma. Current concepts of classification, diagnosis, and management.

In recent years, major advances in the knowledge of immunobiology of the malignant cell, changes in systems of histologic classification and staging procedures, and the development of new therapeutic regimens have considerably changed the approach to, and treatment of, patients with non-Hodgkin's lymphoma. Along with these developments has come the realization that close collaboration among the hematologist-oncologist, the hematopathologist, the radiotherapist, and the surgeon is critical in the successful treatment of these patients. Today, the possibility of cure exists for selected patients with non-Hodgkin's lymphoma; such patients must be identified and given appropriate initial therapy.